Transmedics Group (TMDX) Saham Harga
Transmedics Group Harga
Pendapatan tumbuh 66,3% per tahun selama 9 tahun terakhir menjadi 605,49 Juta. USD. margin bersih Transmedics Group saat ini 31,4%, naik dari -146,1% beberapa tahun lalu. Target harga median analis adalah 95,00 USD, di atas harga saat ini sebesar 1,3%. Dari 19 analis, 14 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Transmedics Group
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Transmedics Group
Pertanyaan yang sering diajukan tentang saham Transmedics Group
Transmedics Group Inc. operates under a business model focused on the development and commercialization of organ transplant solutions. The company specializes in designing and producing innovative medical devices and systems that preserve, monitor, and assess organs intended for transplantation. By harnessing cutting-edge technology, Transmedics' business model aims to improve both donor organ quality and transplantation outcomes. Through its offerings, the company seeks to address critical challenges faced by organ transplant patients and healthcare professionals worldwide. Transmedics Group Inc. continues to drive innovation in the organ transplant field through its comprehensive product portfolio and commitment to advancing patient care.
Transmedics Group Inc is primarily active in the biomedical industry.
The main competitors of Transmedics Group Inc in the market include Medtronic, Inc., XVIVO Perfusion AB, and OrganAssist BV.
Transmedics Group Inc is a leading medical technology company specializing in organ transplant solutions. Founded in 1998, the company has been dedicated to improving outcomes for patients awaiting organ transplants. With its groundbreaking Organ Care System (OCS), Transmedics revolutionized the field by allowing organs to be preserved and assessed outside the traditional cold storage method. This breakthrough technology ensures organs remain at the optimal physiological condition, significantly increasing the chances of successful transplants. Transmedics is committed to continuing innovation and expanding its global presence to address the critical need for organ transplantation worldwide.
Transmedics Group Inc has achieved several significant milestones. Notably, the company successfully developed the Organ Care System (OCS), a breakthrough technology that allows for the preservation and transportation of donor organs. The OCS has revolutionized the field of transplant medicine by extending the time organs can remain outside the body, increasing the chances of successful transplantation. Additionally, Transmedics Group Inc received regulatory approvals for the OCS in major markets, including the United States and Europe. These achievements have solidified the company's position as a leader in the advancement of organ transplantation, benefiting countless patients worldwide.
Transmedics Group Inc is primarily present in the United States.
Transmedics Group Inc represents a commitment to innovation and improving organ transplant outcomes. The company's corporate philosophy centers around its Organ Care System (OCS) technology, which enables the preservation and assessment of donated organs for transplantation. Transmedics Group Inc values the advancements made in organ transplantation, aiming to improve patient outcomes and increase the number of viable organs available for transplant. By leveraging their OCS technology, the company strives to address the critical organ shortage challenge and revolutionize the transplantation field. Through their dedication to innovation and patient-centric approach, Transmedics Group Inc constantly aims to make a positive impact in the field of organ transplantation.
Analis saat ini menetapkan target harga rata-rata 96,86 USD untuk saham Transmedics Group (median: 95,00 USD), yaitu +3,3 % terhadap harga terbaru. Konsensus didasarkan pada 19 peringkat analis.
19 analis saat ini menilai saham Transmedics Group: 14 merekomendasikan beli, 5 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Transmedics Group menghasilkan pendapatan 743,61 Juta. USD dan laba per saham 1,22 USD.
Dengan kurs saat ini, saham Transmedics Group diperdagangkan pada 83,70 EUR (93,79 USD).
Saham Transmedics Group (TMDX) tercatat di 3 bursa, termasuk: NASDAQ (TMDX), Frankfurt (8T8.F), München (8T8.MU).
The Transmedics Group Inc is a leading provider of advanced organ care systems for transplantation medicine. The company offers an innovative platform that allows organs to be obtained, protected, transported, and transplanted outside of the body. The company is divided into three main business areas: 1. Organ Care System The Organ Care System (OCS) is a groundbreaking technology that revolutionizes organ care and transplantation. It is a portable, modular system that enables doctors to obtain and protect donor organs outside of the body. The OCS was developed to increase the survival rate of donor organs and reduce the number of transplant rejections. 2. Organ Transport & Storage Solutions The company offers a variety of organ transport and storage solutions that meet the needs of customers. The transport and storage systems are FDA-certified and provide optimal conditions for successful transplantation. 3. Organ Care Services Organ Care Services (OCS) are a key part of Transmedics' business operations. The company offers a wide range of services tailored to the specific needs of customers. These include organ storage, preparation for transplantation, and support during surgeries. Transmedics is an innovative company protected by a number of patents and intellectual property. The company heavily invests in research and development and stays at the forefront of technology to maintain its position as a leader in organ transplantation. In summary, Transmedics Group Inc is a pioneer in the field of organ transplantation. With its offering of advanced organ care systems, the company has revolutionized transplantation medicine and established itself as a leading provider. Transmedics is well-positioned to continue growing and meeting the needs of its customers while helping to save lives.
Pendapatan diperkirakan dari Transmedics Group adalah 743,61 Juta. USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Transmedics Group adalah 50,08 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Transmedics Group saat ini adalah 76,65. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Transmedics Group.
Rasio harga-terhadap-penjualan (PSR) Transmedics Group saat ini adalah 5,16. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Transmedics Group.
Skor Kualitas AlleAktien untuk Transmedics Group adalah 6/10.
ISIN dari Transmedics Group adalah US89377M1099. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Transmedics Group adalah A2PH5P. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Transmedics Group adalah TMDX. Simbol ticker digunakan untuk memperdagangkan saham Transmedics Group di bursa saham.
Saham Transmedics Group
Kelompok Peer Transmedics Group
Transmedics Group Ticker
Transmedics Group FIGI
Semua metrik fundamental dan analisis mendalam Transmedics Group
Analisis saham kami untuk saham Transmedics Group mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Transmedics Group. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.